Compare Bristol-Myers Squibb Co (BMY) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.45 (market cap $116.30B), while iShares 0 3 Month Treasury Bond ETF trades at $100.54. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while iShares 0 3 Month Treasury Bond ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| BMY | SGOV | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Fixed Income |
52-Week High | $62.37 | $100.74 |
52-Week Low | $42.60 | $100.28 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.52, up 0.02% on the day. The technical outlook is bearish with moving averages signaling caution, while oscillators remain neutral. Recent news highlights strong inflows into cash ETFs amid market volatility and Federal Reserve uncertainty. The fund offers a low-risk haven with a 0.09% expense ratio and yields around 3.54–3.65%, attracting income-focused investors.
The outlook for SGOV is stable, providing a secure parking spot for cash with minimal interest rate risk due to its short duration. Investment opportunity lies in capital preservation and competitive yield versus savings accounts. Primary risks include potential Fed rate cuts reducing yields and high investor concentration in cash-like assets if equity markets rally. The fund suits conservative portfolios seeking liquidity and safety.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
